Sign up for the QMED & MD+DI Daily newsletter.
Sleep Apnea Therapy Hits the Big Time
Philips announced that it will pay $66 per share, or about $5.1 billion, to acquire Respironics, the global leader in the treatment of obstructive sleep apnea, a condition in which patients repeatedly stop breathing during sleep.
December 21, 2007
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "MDDI")
Between 15 million and 20 million people in the United States suffer from it, and it has been linked to heart disease, stroke, and diabetes. Respironics is best known for its continuous positive airway pressure (CPAP) devices, but it offers a number of products for respiratory-impaired patients. The Respironics board of directors has approved the offer and is encouraging shareholders to sign off on it as well.
You May Also Like
.png?width=300&auto=webp&quality=80&disable=upscale)
.png?width=300&auto=webp&quality=80&disable=upscale)
.png?width=300&auto=webp&quality=80&disable=upscale)